FDx Advisors Inc. trimmed its stake in shares of Express Scripts Holding Co (NASDAQ:ESRX) by 82.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,975 shares of the company’s stock after selling 14,041 shares during the quarter. FDx Advisors Inc.’s holdings in Express Scripts were worth $283,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Omni Partners LLP boosted its position in Express Scripts by 22.0% during the second quarter. Omni Partners LLP now owns 281,026 shares of the company’s stock worth $21,698,000 after purchasing an additional 50,664 shares during the period. Marco Investment Management LLC boosted its position in Express Scripts by 168.2% during the second quarter. Marco Investment Management LLC now owns 79,246 shares of the company’s stock worth $6,119,000 after purchasing an additional 49,696 shares during the period. BlackRock Inc. boosted its position in Express Scripts by 1.5% during the second quarter. BlackRock Inc. now owns 35,424,185 shares of the company’s stock worth $2,735,103,000 after purchasing an additional 538,578 shares during the period. Commonwealth Bank of Australia boosted its position in Express Scripts by 15.6% during the second quarter. Commonwealth Bank of Australia now owns 296,858 shares of the company’s stock worth $22,915,000 after purchasing an additional 39,983 shares during the period. Finally, Qube Research & Technologies Ltd boosted its position in Express Scripts by 45.6% during the second quarter. Qube Research & Technologies Ltd now owns 11,749 shares of the company’s stock worth $907,000 after purchasing an additional 3,678 shares during the period. 85.02% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Mahon Thomas P. Mac sold 5,234 shares of the company’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $99.50, for a total transaction of $520,783.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.79% of the company’s stock.

Shares of Express Scripts stock opened at $95.85 on Friday. The stock has a market capitalization of $55.25 billion, a PE ratio of 11.42, a price-to-earnings-growth ratio of 1.23 and a beta of 0.88. Express Scripts Holding Co has a 52-week low of $66.93 and a 52-week high of $101.73. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.77 and a quick ratio of 0.65.

Express Scripts (NASDAQ:ESRX) last announced its earnings results on Wednesday, October 31st. The company reported $2.43 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.01. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. The company had revenue of $25.56 billion during the quarter, compared to analysts’ expectations of $25.11 billion. During the same quarter in the previous year, the business posted $2.51 earnings per share. Express Scripts’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, analysts anticipate that Express Scripts Holding Co will post 9.08 earnings per share for the current year.

ESRX has been the subject of a number of recent research reports. Zacks Investment Research reissued a “buy” rating and issued a $109.00 target price on shares of Express Scripts in a research report on Tuesday, November 13th. BidaskClub raised shares of Express Scripts from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. ValuEngine raised shares of Express Scripts from a “hold” rating to a “buy” rating in a research report on Monday, September 17th. Royal Bank of Canada set a $101.00 target price on shares of Express Scripts and gave the company a “buy” rating in a research report on Thursday, November 1st. Finally, Cowen reissued a “buy” rating and issued a $88.00 target price on shares of Express Scripts in a research report on Friday, November 2nd. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $92.14.

TRADEMARK VIOLATION NOTICE: “Express Scripts Holding Co (ESRX) Shares Sold by FDx Advisors Inc.” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/12/08/express-scripts-holding-co-esrx-shares-sold-by-fdx-advisors-inc.html.

Express Scripts Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Recommended Story: Marijuana Stocks

Want to see what other hedge funds are holding ESRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Express Scripts Holding Co (NASDAQ:ESRX).

Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.